Bausch Health Companies (BHC) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Neurocrine Biosciences (NBIX) has outperformed Bausch Health Companies (BHC) over the past year, gaining 4.7% versus a loss of 3.8%. Over five years, NBIX leads with a +37.2% price change compared with -78.4% for BHC. Neurocrine Biosciences is the larger company by market cap ($14.58 billion vs $2.30 billion), about 6.3 times the size.
On valuation, Bausch Health Companies trades at a lower forward P/E (1.5x vs 12.1x for Neurocrine Biosciences).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | NBIX |
|---|---|---|
| Share price | $6.15 | $143.47 |
| Market cap | $2.30B | $14.58B |
| 1-day change | +2.16% | -1.40% |
| YTD return | -11.51% | +1.16% |
| 1-year return | -3.76% | +4.72% |
| 5-year return | -78.41% | +37.24% |
| P/E ratio (TTM) | — | 21.04 |
| Forward P/E | 1.47 | 12.08 |
| EPS (TTM) | $-2.95 | $6.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.86B |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | — | $478.60M |
| Gross margin | — | 98.18% |
| Operating margin | — | 21.64% |
| Net margin | — | 16.73% |
| 52-week high | $8.00 | $186.12 |
| 52-week low | $4.33 | $122.14 |
| Distance from 52-week high | -23.12% | -22.92% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +21.95% | +44.48% |
| Average volume | 3.26M | 1.30M |
| Shares outstanding | 373.99M | 101.65M |
| Employees | 20,300 | 2,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Neurocrine Biosciences is about 6.3 times larger than Bausch Health Companies by market value ($14.58B vs $2.30B).
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
BHC vs NBIX FAQ
Which is bigger, Bausch Health Companies or Neurocrine Biosciences?
Neurocrine Biosciences (NBIX) is larger, with a market capitalization of $14.58B compared with $2.30B for Bausch Health Companies (BHC).
Which stock has performed better over the past year, BHC or NBIX?
NBIX returned +4.72% over the past 12 months, compared with -3.76% for BHC (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and Neurocrine Biosciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Bausch Health Companies and Biotechnology: Biological Products (No Diagnostic Substances) for Neurocrine Biosciences.